Jim Cassidy

机构：University of Glasgow · ORCID：0000-0003-3917-561X

发表论文 183 篇 · 总被引 17785 次 · h-index 47

代表论文

• Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study (2023 · Journal of Clinical Oncology · 被引 246)
• 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial (2018 · The Lancet Oncology · 被引 191)
• Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX (2017 · European Journal of Cancer · 被引 48)
• Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer (2016 · Oncotarget · 被引 45)
• 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT (2019 · Health Technology Assessment · 被引 38)
• Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer (2023 · Journal of Clinical Oncology · 被引 36)